Drugs / HEC53856
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04925661 | Nov 2021 → Aug 2023 | anemia, chronic kidney disease | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04925674 | Sep 2021 → Oct 2022 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03886688 | May 2019 → Jan 2020 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC53856 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04925661 ↗ |
| Action | Inhibit | “A Novel HIF-PHD Inhibitor” NCT03886688 ↗ |
| Route | Oral | “oral administration” NCT03886688 ↗ |